These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33994737)

  • 1. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.
    Hegde S
    Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):118-127. PubMed ID: 33994737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.
    Zhang J; Wolfgang CL; Zheng L
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29385739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer.
    Group Young Researchers In Inflammatory Carcinogenesis ; Wandmacher AM; Mehdorn AS; Sebens S
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
    Wandmacher AM; Letsch A; Sebens S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
    Alzhrani R; Alsaab HO; Vanamal K; Bhise K; Tatiparti K; Barari A; Sau S; Iyer AK
    Adv Ther (Weinh); 2021 Jun; 4(6):. PubMed ID: 34212073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?
    Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in precision medicine in pancreatic cancer: A focus in cancer stem cells and microbiota.
    Perelló-Reus CM; Rubio-Tomás T; Cisneros-Barroso E; Ibargüen-González L; Segura-Sampedro JJ; Morales-Soriano R; Barceló C
    Front Oncol; 2022; 12():995357. PubMed ID: 36531066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer.
    Lee B; Gibbs P
    J Pers Med; 2019 Apr; 9(2):. PubMed ID: 31035449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer.
    Regel I; Mayerle J; Mahajan UM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular therapeutics in pancreas cancer.
    Narayanan V; Weekes CD
    World J Gastrointest Oncol; 2016 Apr; 8(4):366-79. PubMed ID: 27096032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling pancreatic cancer in mice for experimental therapeutics.
    Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
    Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for MYC imaging and targeting in pancreatic cancer.
    Schneider G; Wirth M; Keller U; Saur D
    EJNMMI Res; 2021 Oct; 11(1):104. PubMed ID: 34637026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
    Sereti E; Papapostolou I; Dimas K
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects.
    Polani F; Grierson PM; Lim KH
    World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.